A simple method for deriving functional MSCs and applied for osteogenesis in 3D scaffolds.

Current research in tissue engineering seeks reliable sources of stem cells for bone regeneration. Prior studies have demonstrated that mesenchymal stem cells (MSCs) can differentiate into osteoblasts, but sourcing these cells remains a challenge. Human induced-pluripotent stem cells (hiPSCs) offer a potential solution by allowing MSC derivation from patient-specific sources. However, the functional capacity of hiPSC-derived MSCs in bone formation has not been fully explored. This gap motivates the need to assess the osteogenic potential of hiPSC-derived MSCs in 3D scaffolds. Previous findings suggest that these cells can express mesenchymal markers but retain some pluripotency markers. No prior work had resolved whether these cells maintain full osteogenic function in scaffold-based systems. This uncertainty drives the current investigation. The study aims to clarify whether hiPSC-derived MSCs can support calcified tissue formation in synthetic and hybrid scaffolds. Understanding this could advance personalized orthopedic therapies. The research builds on established knowledge of MSC differentiation and scaffold integration. It seeks to bridge the gap between stem cell derivation and functional tissue engineering.

The goal of this research was to evaluate the osteogenic potential of hiPSC-derived MSCs in 3D scaffolds. The authors aimed to determine whether these cells retain full osteogenic function after derivation from hiPSCs. They also sought to assess compatibility with two scaffold types: synthetic polycaprolactone (PCL) and a hybrid of PCL with hyaluronan and tricalcium phosphate (PHT). The study aimed to confirm that these cells can form calcified structures in vitro and in vivo. The authors focused on functional compatibility and structural outcomes in the scaffolds. They tested whether the cells could maintain mesenchymal characteristics while losing pluripotency markers. The study aimed to provide a foundation for future personalized orthopedic therapies. The research aimed to demonstrate that hiPSC-derived MSCs are viable for bone tissue engineering applications.

The researchers used human induced-pluripotent stem cells (hiPSCs) to derive mesenchymal stem cells (MSCs). They confirmed mesenchymal marker expression (CD90, CD73, CD105) and tri-lineage differentiation potential. They assessed pluripotency marker loss (OCT3/4, TRA-1-81) and tumorigenicity. The hiPSC-derived MSCs were seeded onto two scaffold types: polycaprolactone (PCL) and a composite of PCL with hyaluronan and tricalcium phosphate (PHT). The cells were cultured in osteogenic media to induce bone formation. The study included in vitro and in vivo experiments to evaluate calcified structure formation. They used histological and biochemical methods to assess osteogenic outcomes. The researchers compared scaffold compatibility and calcification in both synthetic and hybrid materials.

The hiPSC-derived MSCs expressed mesenchymal markers and demonstrated tri-lineage differentiation potential. These cells lost pluripotency markers OCT3/4 and TRA-1-81 but remained positive for NANOG. The cells were compatible with both PCL and PHT scaffolds in vitro. In vivo, the cells formed calcified structures within the scaffolds. Histological analysis confirmed the presence of calcified nodules in the PCL and PHT groups. Biochemical assays showed increased alkaline phosphatase activity and calcium deposition. The results suggest that the cells retained full osteogenic function after derivation. The study found no evidence of tumorigenicity in the derived MSCs.

The authors conclude that hiPSC-derived MSCs retain full osteogenic function after derivation. These cells are compatible with both synthetic and hybrid scaffolds used in the study. The results suggest that these cells can form calcified structures in vitro and in vivo. The study confirms the loss of pluripotency markers but retention of NANOG. The findings indicate that hiPSC-derived MSCs are suitable for bone tissue engineering. The authors propose that this method provides a new solution for personalized orthopedic therapy. The results support the use of hiPSC-derived MSCs in scaffold-based bone regeneration. The study highlights the potential of these cells for future clinical applications.